Drug-Resistant Bacteria, Dengue Expansion, and a Gene Therapy Milestone for Mediterranean Patients

The first days of September 2026 have brought a cluster of significant public-health and clinical developments — from a sobering European antimicrobial resistance reckoning to a long-sought biomarker for long-COVID, a dengue fever expansion alert, and a milestone for patients with sickle cell disease in Cyprus and Greece.

Thursday, 10 September: WHO and ECDC Report Drug-Resistant Bacteria Now Kill More Europeans Than Road Accidents

The 2026 joint WHO/ECDC European Antimicrobial Resistance Surveillance Summary estimates that more than 400,000 deaths in Europe are now attributable each year to infections caused by drug-resistant bacteria — surpassing road traffic accidents as a preventable cause of premature mortality. The report identifies Escherichia coli and Klebsiella pneumoniae carrying carbapenem-resistant genes as the strains spreading most rapidly, particularly in southern European countries including Greece, Italy, and Cyprus. The ECDC flagged that broad-spectrum antibiotic use in outpatient settings across the EU remains well above targets, and that resistance to third- and fourth-generation antibiotics has increased in nearly every member state over the past decade. The report calls for accelerating national antimicrobial stewardship programmes, restricting over-the-counter antibiotic sales — still legal in several EU member states — and urgently increasing investment in novel antibiotic development pipelines, which remain critically underfunded relative to the scale of the threat.

Thursday, 10 September: German Phase 2 Trial Confirms CAR-T Cell Therapy Induces Sustained Remission in Severe Autoimmune Disease

A phase 2 study published in Nature Medicine by researchers at Erlangen University Hospital reports that a single course of CD19-targeting CAR-T cell therapy induced drug-free clinical remission in patients with refractory systemic lupus erythematosus and inflammatory myopathy — two serious autoimmune conditions with limited treatment options. Follow-up in the earliest-treated patients extended to two years. Those who responded were able to discontinue immunosuppressive medications without relapse, and none experienced cytokine release syndrome above grade 2, the serious complication that has historically limited CAR-T use to oncology. The trial enrolled 35 participants, and the researchers caution that longer follow-up in larger cohorts is needed before routine clinical use. Nevertheless, the result extends a scientific signal first glimpsed in single-patient case reports and represents an important step in repurposing cellular immunotherapy — developed for blood cancers — for severe immune-mediated disease more broadly.

Wednesday, 9 September: ECDC Raises Dengue Risk Assessment After Local Transmission Confirmed in Three EU Mediterranean Countries

The European Centre for Disease Prevention and Control has upgraded its risk assessment for locally-acquired dengue fever following confirmed cases with no recent travel history in Spain, Italy, and Greece during this summer. The expansion reflects the continued northward spread of Aedes albopictus — the tiger mosquito — driven by warming Mediterranean summers and increased urban standing water in which the insect breeds. Dengue causes high fever, severe muscle and joint pain, and in a minority of cases haemorrhagic complications requiring hospital care. There is no specific antiviral treatment; management is supportive. The WHO notes that dengue now circulates in more than 100 countries, with European incidence rising sharply over the past decade. ECDC urged Mediterranean member states to reinforce integrated mosquito surveillance and to update traveller health advisories. The Cyprus Department of Medical and Public Health Services confirmed active surveillance and advised residents to eliminate standing water around homes and gardens, particularly in coastal and urban areas where tiger mosquito populations have been detected in recent seasons.

Wednesday, 9 September: Multicentre European Cohort Identifies Blood Protein Signature That Predicts Long-COVID at One Year

A large multicentre study published in The Lancet identified a panel of blood proteins — primarily markers of persistent inflammatory activation and abnormal coagulation — measurable within six weeks of SARS-CoV-2 infection, that predicts with substantial accuracy which patients will develop persistent long-COVID symptoms at twelve months. The cohort enrolled more than 6,000 participants across six European countries, including both hospitalised and non-hospitalised COVID-19 cases. Individuals whose early protein signature fell in the high-risk category were significantly more likely to report fatigue, cognitive difficulty, and breathlessness at one year than those with a normal pattern. The researchers emphasise that the test is not yet ready for routine clinical use — validation in independent cohorts is ongoing — but that the findings open a pathway toward early-intervention trials targeting the underlying inflammatory and clotting abnormalities. Long-COVID is estimated to affect between 5 and 10 percent of people following SARS-CoV-2 infection and remains one of the largest unresolved public-health burdens of the post-pandemic period.

Tuesday, 8 September: WHO Europe Releases Updated Primary Care Mental Health Guidelines Amid Widening Treatment Gap

The World Health Organization's Regional Office for Europe published the first major revision of its mental health integration guidelines for primary care settings since 2018. The updated framework recommends that general practitioners and family medicine physicians implement same-day psychological first aid, digital symptom-screening tools for depression and anxiety, and structured stepped-care referral protocols that match treatment intensity to symptom severity. WHO Europe estimates that between 35 and 45 percent of people in EU member states experiencing depression, anxiety, or psychosis currently receive no formal care. The guidelines respond to a post-pandemic surge in demand for mental health services that has outpaced workforce growth across the region. Cyprus, Greece, and several eastern Mediterranean countries are specifically cited in an accompanying policy note as countries with particularly high treatment gaps relative to estimated prevalence, and are encouraged to integrate mental health nurses and community mental health workers into primary care teams.

Tuesday, 8 September: First Mediterranean Patients Receive EMA-Approved Sickle Cell Gene Therapy in Cyprus and Greece

The first patients in Cyprus and Greece are receiving EMA-approved gene therapy for sickle cell disease, following the conclusion of national reimbursement negotiations, medical teams in both countries confirmed this week. Cyprus and Greece carry among the highest rates of haemoglobin S and beta-thalassaemia gene variants in Europe — a legacy of historical malaria endemicity — meaning their populations have a disproportionately high burden of haemoglobinopathies. Gene therapy offers the prospect of a curative or near-curative outcome through a single treatment, either adding a functional copy of the affected haemoglobin gene or, in one approved approach, using CRISPR-based editing to reactivate a foetal haemoglobin pathway. The principal barrier to access has been cost: approved treatments are priced in the range of €1.5–2 million per patient. Patient groups and haematologists in both countries welcomed the reimbursement decision as long-overdue recognition of the community's disease burden and the transformative potential of these therapies for younger patients who might otherwise require decades of transfusion support.

The content in this article is journalistic reporting compiled for informational purposes and is not intended as medical advice. Readers should consult a qualified clinician before making any changes to their treatment, medication, or healthcare plan.